CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ligand Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ligand Pharmaceuticals Inc
555 Heritage Drive,
Suite 200
Phone: (302) 636-5401p:302 636-5401 JUPITER, FL  33458  United States Ticker: LGNDLGND
Business Summary
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board John W.Kozarich 76 3/1/2017 3/6/2003
Chief Executive Officer, Director Todd C.Davis 65 12/5/2022 3/1/2007
Chief Financial Officer OctavioEspinoza 55 11/1/2022 9/1/2020
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
LIGAND UK LIMITED C/0 LEGALINX LIMITED TALLIS HOUSE UK
LIGAND HOLDINGS UK LTD. C/O LEGALINX LIMITED TALLIS HOUSE UK
LIGAND UK DEVELOPMENT LIMITED C/O LEGALINX LIMITED TALLIS HOUSE UK
21 additional Subsidiary records available in full report.

Business Names
Business Name
APEIRON Biologics AG
Apeiron Biologics GmbH
CyDex Pharmaceuticals, Inc.
33 additional Business Names available in full report.

General Information
Number of Employees: 47 (As of 12/31/2025)
Outstanding Shares: 20,041,061 (As of 5/5/2026)
Shareholders: 305
Stock Exchange: NASD
Federal Tax Id: 770160744
Fax Number: (302) 636-5454
Email Address: INVESTORS@LIGAND.COM


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, July 26, 2026